Quick generic drug news for today. If you or a loved one suffers from hepatitis B, it’s bad news. Bristol-Myers Squibb has filed a lawsuit against Novartis to stop its generic version of hepatitis B drug Baraclude. Bristol-Myers filed the lawsuit last month against Novartis in U.S. District Court for the District of Delaware, accusing the generic drug company of infringing itsBaraclude patents.
The Food and Drug Administration has approved Baraclude to treat chronic hepatitis B virus (HBV) in adults who have active virus and liver damage.
Considering a thirty-day supply of brand-name Frova is currently running almost $1,000, a generic version of Baraclude could easily be a major savings for many hepatitis B patients. We have our fingers crossed on this one, and you can be sure we’ll keeping an eye on when a generic version of Baraclude will be able to hit the market!
Do you or someone you love take Baraclude for hepatitis B? Tell us about it in our prescription drug forum!
Join the forum discussion on this post
Related posts:
- Generic Drug News: Pfizer Wins Suit To Block Generic Lyrica
- Generic Drug News: Novartis Sues to Block Generic Zometa, Generic Reclast
- Generic Drug News: Sandoz Files Suit to Release Generic Version of Diabetes Drug Prandin
- Generic Drug News: Endo Files Lawsuit to Block Generic Version of Migraine Drug Frova
- Generic Drug News: Pfizer Files Lawsuit to Block Generic Version of Pain Drug Lyrica
Loading ...
Follow Us!